Yamanouchi Terminates Marketing Agreement With Daiichi Suntory

Yamanouchi Pharmaceutical has announced that is has agreed with Daiichi Suntory Pharma to terminate a marketing agreement between the two companies regarding the penem-type antibiotic Farom (faropenem sodium) on March 31, 2005. After April 1, 2005, all marketing and detailing activities will be conducted by Maruho. In the fiscal year ended in March 2004, Yamanouchi posted sales of about 3.4 billion yen with these products.

Japan Corporate News (http://www.japancorp.net/Article.Asp?Art_ID=9437)